Hydrocodone Bitartrate And Ibuprofen
Generic Name: hydrocodone bitartrate and ibuprofen
Brand Names:
Hydrocodone Bitartrate And Ibuprofen
DESCRIPTION Each hydrocodone bitartrate and ibuprofen tablet contains: Hydrocodone Bitartrate, USP 7.5 mg Ibuprofen, USP 200 mg Hydrocodone Bitartrate and Ibuprofen Tablets are supplied in a fixed combination tablet form for oral administration. Hydrocodone Bitartrate and Ibuprofen Tablets combines the opioid agonist agent, hydrocodone bitartrate, with the nonsteroidal anti-inflammatory (NSAID) agent, ibuprofen. Hydrocodone bitartrate is a semisynthetic opioid agonist.
Overview
DESCRIPTION Each hydrocodone bitartrate and ibuprofen tablet contains: Hydrocodone Bitartrate, USP 7.5 mg Ibuprofen, USP 200 mg Hydrocodone Bitartrate and Ibuprofen Tablets are supplied in a fixed combination tablet form for oral administration. Hydrocodone Bitartrate and Ibuprofen Tablets combines the opioid agonist agent, hydrocodone bitartrate, with the nonsteroidal anti-inflammatory (NSAID) agent, ibuprofen. Hydrocodone bitartrate is a semisynthetic opioid agonist.
Uses
INDICATIONS AND USAGE Hydrocodone Bitartrate and Ibuprofen Tablets are indicated for the short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Carefully consider the potential benefits and risks of Hydrocodone Bitartrate and Ibuprofen Tablets and other treatment options before deciding to use Hydrocodone Bitartrate and Ibuprofen Tablets Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see WARNINGS: Cardiovascular Thrombotic Events, Gastrointestinal Bleeding, Ulceration, and Perforation ). Do not use Hydrocodone Bitartrate and Ibuprofen Tablets for the treatment of conditions such as osteoarthritis or rheumatoid arthritis.
Dosage
DOSAGE AND ADMINISTRATION Hydrocodone Bitartrate and Ibuprofen Tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see Warnings]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of Hydrocodone Bitartrate and Ibuprofen Tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.
Side Effects
ADVERSE REACTIONS The following adverse reactions are described below and elsewhere in the labeling including the WARNINGS section. Addiction, Abuse, and Misuse Life-Threatening Respiratory Depression Neonatal Opioid Withdrawal Syndrome Interactions with Cytochrome P450 3A4 Inhibitors and Inducers Interactions with Benzodiazepines or Other CNS Depressants Adrenal Insufficiency Severe Hypotension Seizures Withdrawal Cardiovascular Thrombotic Events Gastrointestinal Bleeding, Ulceration, and Perforation Hepatotoxicity Hypertension Heart Failure and Edema Renal Toxicity and Hyperkalemia Anaphylactic Reactions Exacerbation of Asthma Related to Aspirin Sensitivity Serious Skin Reactions Premature Closure of Fetal Ductus Arteriosus Hematologic Toxicity Aseptic Meningitis Opioid-Induced Hyperalge...
Interactions
Drug Interactions Inhibitors of CYP3A4 and CYP2D6 The concomitant use of hydrocodone bitartrate and ibuprofen tablets and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir), can increase the plasma concentration of hydrocodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of hydrocodone bitartrate and ibuprofen tablets and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of hydrocodone bitartrate and ibuprofen tablets are achieved (see WARNINGS: Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers ).
Warnings
WARNING: ADDICTION, ABUSE, AND MISUSE:RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction, Abuse, and Misuse Because the use of Hydr... WARNINGS Hydrocodone Component Addiction, Abuse, and Misuse Hydrocodone Bitartrate and Ibuprofen Tablets contains hydrocodone, a Schedule II controlled substance. As an opioid- containing product, Hydrocodone Bitartrate and Ibuprofen Tablets exposes users to the risks of addiction, abuse, and misuse (see DRUG ABUSE AND DEPENDENCE). Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Hydrocodone Bitartrate and Ibuprofen Tablets. Addiction can occur at recommended dosages and if the drug is misused or abused.The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. CONTRAINDICATIONS Hydrocodone Bitartrate and Ibuprofen Tablets are contraindicated in patients with: Significant respiratory depression (see WARNINGS: Life-Threatening Respiratory Depression ).
Pregnancy
Pregnancy Risk Summary Use of NSAIDs, including Hydrocodone Bitartrate and Ibuprofen Tablets, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of Hydrocodone Bitartrate and Ibuprofen Tablets use between about 20 and 30 weeks of gestation, and avoid Hydrocodone Bitartrate and Ibuprofen Tablets use at about 30 weeks of gestation and later in pregnancy (see WARNINGS; Fetal Toxicity ).
Storage
HOW SUPPLIED Hydrocodone Bitartrate and Ibuprofen Tablets, 7.5 mg/200 mg are white to off-white, round, film coated tablets, debossed with “U13” on one side and plain on the other side. Bottles of 10 NDC 13107-004-11 Bottles of 100 NDC 13107-004-01 Bottles of 500 NDC 13107-004-05 Bottles of 1,000 NDC 13107-004-99 Storage Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Frequently Asked Questions
What is Hydrocodone Bitartrate And Ibuprofen used for?▼
INDICATIONS AND USAGE Hydrocodone Bitartrate and Ibuprofen Tablets are indicated for the short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Carefully consider the potential benefits and risks of Hydrocodone Bitartrate and Ibuprofen Tablets and other treatment options before deciding to use Hydrocodone Bitartrate and Ibuprofen Tablets Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see WARNINGS: Cardiovascular Thrombotic Events, Gastrointestinal Bleeding, Ulceration, and Perforation ). Do not use Hydrocodone Bitartrate and Ibuprofen Tablets for the treatment of conditions such as osteoarthritis or rheumatoid arthritis.
What are the side effects of Hydrocodone Bitartrate And Ibuprofen?▼
ADVERSE REACTIONS The following adverse reactions are described below and elsewhere in the labeling including the WARNINGS section. Addiction, Abuse, and Misuse Life-Threatening Respiratory Depression Neonatal Opioid Withdrawal Syndrome Interactions with Cytochrome P450 3A4 Inhibitors and Inducers Interactions with Benzodiazepines or Other CNS Depressants Adrenal Insufficiency Severe Hypotension Seizures Withdrawal Cardiovascular Thrombotic Events Gastrointestinal Bleeding, Ulceration, and Perforation Hepatotoxicity Hypertension Heart Failure and Edema Renal Toxicity and Hyperkalemia Anaphylactic Reactions Exacerbation of Asthma Related to Aspirin Sensitivity Serious Skin Reactions Premature Closure of Fetal Ductus Arteriosus Hematologic Toxicity Aseptic Meningitis Opioid-Induced Hyperalge...
Can I take Hydrocodone Bitartrate And Ibuprofen during pregnancy?▼
Pregnancy Risk Summary Use of NSAIDs, including Hydrocodone Bitartrate and Ibuprofen Tablets, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of Hydrocodone Bitartrate and Ibuprofen Tablets use between about 20 and 30 weeks of gestation, and avoid Hydrocodone Bitartrate and Ibuprofen Tablets use at about 30 weeks of gestation and later in pregnancy (see WARNINGS; Fetal Toxicity ).
What are the important warnings for Hydrocodone Bitartrate And Ibuprofen?▼
WARNING: ADDICTION, ABUSE, AND MISUSE:RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction, Abuse, and Misuse Because the use of Hydr... WARNINGS Hydrocodone Component Addiction, Abuse, and Misuse Hydrocodone Bitartrate and Ibuprofen Tablets contains hydrocodone, a Schedule II controlled substance. As an opioid- containing product, Hydrocodone Bitartrate and Ibuprofen Tablets exposes users to the risks of addiction, abuse, and misuse (see DRUG ABUSE AND DEPENDENCE). Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed Hydrocodone Bitartrate and Ibuprofen Tablets. Addiction can occur at recommended dosages and if the drug is misused or abused.The risk of opioid-related overdose or overdose-related death is increased with higher opioid doses, and this risk persists over the course of therapy. CONTRAINDICATIONS Hydrocodone Bitartrate and Ibuprofen Tablets are contraindicated in patients with: Significant respiratory depression (see WARNINGS: Life-Threatening Respiratory Depression ).
Related Medications
Allium Sativum, Apis Mellifica, Argentum Metallicum, Calcarea Fluorica, Caltha Palustris, Clematis Erecta, Echinacea (angustifolia), Galium Aparine, Hedera Helix, Juniperus Communis, Nitricum Acidum, Ononis Spinosa, Phosphorus, Pyrogenium, Sedum Acre, Sempervivum Tectorum, Thuja Occidentalis, Urtica Urens
allium sativum, apis mellifica, argentum metallicum, calcarea fluorica, caltha palustris, clematis erecta, echinacea (angustifolia), galium aparine, hedera helix, juniperus communis, nitricum acidum, ononis spinosa, phosphorus, pyrogenium, sedum acre, sempervivum tectorum, thuja occidentalis, urtica urens
Standardized Insect Venom Allergenic Extract [EPC]
PURPOSE: Allium Sativum - Muscle Pain, Apis Mellifica – Joint Pain, Argentum Metallicum - Fever, Calcarea Fluorica - Chills, Caltha Palustris – GI Pain, Clematis Erecta – Nose Congestion, Echinacea (Angustifolia) – Sinus Congestion, Galium Aparine – Irritated Throat, Hedera Helix – GI Pain, Juniperus Communis – Joint Pain, Nitricum Acidum – Muscle Pain, Ononis Spinosa – GI Pain, Phosphorus - Fever, Pyrogenium – Chills, Sedum Acre - Fever, Sempervivum Tectorum – Irritated Throat, Thuja Occidental
Hexaminolevulinate Hydrochloride
hexaminolevulinate hydrochloride
11 DESCRIPTION Cysview contains hexaminolevulinate hydrochloride, an optical imaging drug that in solution form is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy. The chemical formula for hexaminolevulinate hydrochloride is C 11 H 21 NO 3 ∙HCl.
Myrrha, Trigonella Foenum-graecum, Pinus Sylvestris, Lymph (suis), Spleen (suis), Conium Maculatum, Echinacea (angustifolia), Hepar Sulphuris Calcareum, Hydrangea Arborescens, Phytolacca Decandra, Silicea
myrrha, trigonella foenum-graecum, pinus sylvestris, lymph (suis), spleen (suis), conium maculatum, echinacea (angustifolia), hepar sulphuris calcareum, hydrangea arborescens, phytolacca decandra, silicea
INDICATIONS: For temporary relief of swollen tonsils or sore throat and swollen irritable breasts prior to menses.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.